Clinical Trials
59 trialsPEMIGIST
Dana-Farber Cancer Institute
SAVE-GEJ
Peking University People's Hospital
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Peking University Cancer Hospital & Institute
ATEZOGIST
Centre Leon Berard
GIST
Asan Medical Center
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
GIST Oral Paclitaxel(Liporaxel)
Asan Medical Center
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
Asan Medical Center
SUR-CAN
Centre Oscar Lambret
Imatinib TDM in GIST
University of Kentucky
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
M.D. Anderson Cancer Center
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Sarcoma Alliance for Research through Collaboration
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
CYCLIGIST
Institut Bergonié
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Asan Medical Center
A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment
Peking University
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
University of California, San Diego
Epacadostat and Pembrolizumab in Patients With GIST
Columbia University
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
Asan Medical Center
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
Centre Leon Berard
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
REGISTRI
Grupo Espanol de Investigacion en Sarcomas
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Asan Medical Center
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
Jonsson Comprehensive Cancer Center
ZJGIST-01
First Affiliated Hospital of Zhejiang University
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Dana-Farber Cancer Institute
Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy
M.D. Anderson Cancer Center
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
Asan Medical Center
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Asan Medical Center
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Asan Medical Center
Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
Asan Medical Center
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
PRIORITY
Asan Medical Center
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
Swiss Cancer Institute
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Chang Gung Memorial Hospital
Trial of Dasatinib in Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
Sarcoma Alliance for Research through Collaboration
POETIG
Universität Duisburg-Essen
PAGIST
Scandinavian Sarcoma Group
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
Stanford University
Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
University of Utah
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
SCRI Development Innovations, LLC
Quick Skin Sealant in Closure of Surgical Wound After Laparoscopic Surgery
First Affiliated Hospital, Sun Yat-Sen University
A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
National Health Research Institutes, Taiwan
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Peking University
STS
National Health Research Institutes, Taiwan
07060
Fox Chase Cancer Center